Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

ABSTRACT:

Purpose

The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting.

Patients and methods

Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored.

Results

Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of

SUBMITTER: Cowey CL 

PROVIDER: S-EPMC4525128 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature